Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jul;40(7):1733–1735. doi: 10.1128/aac.40.7.1733

Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock.

F Genovese 1, G Mancuso 1, M Cuzzola 1, V Cusumano 1, F Nicoletti 1, K Bendtzen 1, G Teti 1
PMCID: PMC163407  PMID: 8807074

Abstract

Unlike the antibiotics erythromycin and penicillin G, sodium fusidate (fusidin) pretreatment (80 mg/kg of body weight) increased the survival rate of neonatal BALB/c mice challenged with Salmonella enteritidis lipopolysaccharide. Fusidin also significantly reduced the plasma tumor necrosis factor alpha levels. Hence, fusidin may prove useful in the management of bacterial sepsis in humans.

Full Text

The Full Text of this article is available as a PDF (228.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beal A. L., Cerra F. B. Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA. 1994 Jan 19;271(3):226–233. [PubMed] [Google Scholar]
  2. Bendtzen K., Diamant M., Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine. 1990 Nov;2(6):423–429. doi: 10.1016/1043-4666(90)90051-t. [DOI] [PubMed] [Google Scholar]
  3. Bendtzen K. Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity. Immunol Lett. 1988 Nov;19(3):183–191. doi: 10.1016/0165-2478(88)90141-1. [DOI] [PubMed] [Google Scholar]
  4. Car B. D., Eng V. M., Schnyder B., Ozmen L., Huang S., Gallay P., Heumann D., Aguet M., Ryffel B. Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med. 1994 May 1;179(5):1437–1444. doi: 10.1084/jem.179.5.1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cerami A. Tumor necrosis factor as a mediator of shock, cachexia and inflammation. Blood Purif. 1993;11(2):108–117. doi: 10.1159/000170104. [DOI] [PubMed] [Google Scholar]
  6. Dinarello C. A. Interleukin-1 and interleukin-1 antagonism. Blood. 1991 Apr 15;77(8):1627–1652. [PubMed] [Google Scholar]
  7. Emerson T. E., Jr, Lindsey D. C., Jesmok G. J., Duerr M. L., Fournel M. A. Efficacy of monoclonal antibody against tumor necrosis factor alpha in an endotoxemic baboon model. Circ Shock. 1992 Oct;38(2):75–84. [PubMed] [Google Scholar]
  8. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986 Dec 4;95(1):99–105. doi: 10.1016/0022-1759(86)90322-4. [DOI] [PubMed] [Google Scholar]
  9. GODTFREDSEN W. O., JAHNSEN S., LORCK H., ROHOLT K., TYBRING L. Fusidic acid: a new antibiotic. Nature. 1962 Mar 10;193:987–987. doi: 10.1038/193987a0. [DOI] [PubMed] [Google Scholar]
  10. Heinzel F. P. The role of IFN-gamma in the pathology of experimental endotoxemia. J Immunol. 1990 Nov 1;145(9):2920–2924. [PubMed] [Google Scholar]
  11. Jarvis W. R. Epidemiology of nosocomial infections in pediatric patients. Pediatr Infect Dis J. 1987 Apr;6(4):344–351. doi: 10.1097/00006454-198704000-00003. [DOI] [PubMed] [Google Scholar]
  12. Jesmok G., Lindsey C., Duerr M., Fournel M., Emerson T., Jr Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. coli-challenged swine. Am J Pathol. 1992 Nov;141(5):1197–1207. [PMC free article] [PubMed] [Google Scholar]
  13. Leonard E. M., van Saene H. K., Shears P., Walker J., Tam P. K. Pathogenesis of colonization and infection in a neonatal surgical unit. Crit Care Med. 1990 Mar;18(3):264–269. doi: 10.1097/00003246-199003000-00003. [DOI] [PubMed] [Google Scholar]
  14. Lynn W. A., Cohen J. Adjunctive therapy for septic shock: a review of experimental approaches. Clin Infect Dis. 1995 Jan;20(1):143–158. doi: 10.1093/clinids/20.1.143. [DOI] [PubMed] [Google Scholar]
  15. Mancuso G., Cusumano V., Cook J. A., Smith E., Squadrito F., Blandino G., Teti G. Efficacy of tumor necrosis factor alpha and eicosanoid inhibitors in experimental models of neonatal sepsis. FEMS Immunol Med Microbiol. 1994 Jun;9(1):49–54. doi: 10.1111/j.1574-695X.1994.tb00473.x. [DOI] [PubMed] [Google Scholar]
  16. Mancuso G., Tomasello F., Migliardo M., Delfino D., Cochran J., Cook J. A., Teti G. Beneficial effects of interleukin-6 in neonatal mouse models of group B streptococcal disease. Infect Immun. 1994 Nov;62(11):4997–5002. doi: 10.1128/iai.62.11.4997-5002.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Morrison D. C., Ryan J. L. Endotoxins and disease mechanisms. Annu Rev Med. 1987;38:417–432. doi: 10.1146/annurev.me.38.020187.002221. [DOI] [PubMed] [Google Scholar]
  18. Natanson C., Hoffman W. D., Suffredini A. F., Eichacker P. Q., Danner R. L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med. 1994 May 1;120(9):771–783. doi: 10.7326/0003-4819-120-9-199405010-00009. [DOI] [PubMed] [Google Scholar]
  19. Nicoletti F., Di Marco R., Morrone S., Zaccone P., Lembo D., Grasso S., Santoni A., Meroni P. L., Bendtzen K. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology. 1994 Feb;81(2):317–321. [PMC free article] [PubMed] [Google Scholar]
  20. Nicoletti F., Meroni P. L., Lunetta M., Vigo R., Palermo T., Papalia D., Barcellini W., Di Mauro M., Caruso-Nicoletti M., Mughini L. Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet. 1991 May 25;337(8752):1292–1292. doi: 10.1016/0140-6736(91)92964-4. [DOI] [PubMed] [Google Scholar]
  21. Nicoletti F., Zaccone P., Di Marco R., Magro G., Grasso S., Morrone S., Santoni A., Tempera G., Meroni P. L., Bendtzen K. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology. 1995 Aug;85(4):645–650. [PMC free article] [PubMed] [Google Scholar]
  22. Reeves D. S. The pharmacokinetics of fusidic acid. J Antimicrob Chemother. 1987 Oct;20(4):467–476. doi: 10.1093/jac/20.4.467. [DOI] [PubMed] [Google Scholar]
  23. Teti G., Mancuso G., Tomasello F. Cytokine appearance and effects of anti-tumor necrosis factor alpha antibodies in a neonatal rat model of group B streptococcal infection. Infect Immun. 1993 Jan;61(1):227–235. doi: 10.1128/iai.61.1.227-235.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Tracey K. J., Fong Y., Hesse D. G., Manogue K. R., Lee A. T., Kuo G. C., Lowry S. F., Cerami A. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 1987 Dec 17;330(6149):662–664. doi: 10.1038/330662a0. [DOI] [PubMed] [Google Scholar]
  25. Verhoef J., Mattsson E. The role of cytokines in gram-positive bacterial shock. Trends Microbiol. 1995 Apr;3(4):136–140. doi: 10.1016/s0966-842x(00)88902-7. [DOI] [PubMed] [Google Scholar]
  26. Zeller W. P., Goto M., Witek-Janusek L., Hurley R. M. Mortality, temporal substrate and insulin responses to endotoxic shock in zero, ten and twenty-eight day old rats. Surg Gynecol Obstet. 1991 Nov;173(5):375–383. [PubMed] [Google Scholar]
  27. von Daehne W., Godtfredsen W. O., Rasmussen P. R. Structure-activity relationships in fusidic acid-type antibiotics. Adv Appl Microbiol. 1979;25:95–146. doi: 10.1016/s0065-2164(08)70148-5. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES